The double-blind, randomised, placebo-controlled study (“PSILAUT”) will investigate whether there is a difference in the function of serotonin brain networks in autistic and non-autistic adults. The researchers will use a range of imaging techniques and behavioural tasks to examine how the serotonin system is modulated by COMP360 psilocybin.
It is an investigator-initiated exploratory study that will take place at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London. The study is co-sponsored by King’s IoPPN and South London and Maudsley NHS Foundation Trust. It will enrol 70 adult participants, including 40 autistic people and 30 non-autistic people.
Topic Autism
Compound Psilocybin
Country United Kingdom
Visit trial
Status
Planned
Results Published
Chance of happening
89%
Phase
Phase II
Design
Blinded
Type
Interventional
Generation
Second
Participants
70
Sex
All
Age
18- 99
Therapy
No
Trial Details
NCT Number
Sponsors & Collaborators
COMPASS PathwaysCOMPASS Pathways is a publicly listed company (NASDAQ) that is developing psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. COMPASS is one of the largest psychedelic companies and has received substantial investment from atai.
King's College London
The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London is one of Europe's top centres for mental health and related neurosciences research.
South London and Maudsley NHS Foundation Trust
The South London and Maudsley NHS Foundation Trust provide the widest range of NHS mental health services in the UK. The trust has recently expanded its research into psychedelic therapies.